Loading…
Incidence of diabetes mellitus-related comorbidities among patients attending two major HIV clinics in Botswana: a 12-year retrospective cohort study
Exposure to combination antiretroviral therapy (cART) is associated with the development of diabetes mellitus related comorbidities (DRCs). This study aims to: (i) estimate the incidence of DRCs among cART recipients, (ii) assess the time-to-event (development of DRC) and, (iii) compare survival fun...
Saved in:
Published in: | BMC research notes 2018-02, Vol.11 (1), p.90-90, Article 90 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c5099-b3792cce32a9bc9c45eb3c125b92960b278c0cb699540d7e93618b1e3f4319ce3 |
---|---|
cites | cdi_FETCH-LOGICAL-c5099-b3792cce32a9bc9c45eb3c125b92960b278c0cb699540d7e93618b1e3f4319ce3 |
container_end_page | 90 |
container_issue | 1 |
container_start_page | 90 |
container_title | BMC research notes |
container_volume | 11 |
creator | Rankgoane-Pono, Goabaone Tshikuka, Jose Gaby Magafu, Mgaywa Gilbert Mjungu Damas Masupe, Tiny Molefi, Mooketsi Hamda, Shimeles Genna Setlhare, Vincent Tapera, Roy Mbongwe, Bontle |
description | Exposure to combination antiretroviral therapy (cART) is associated with the development of diabetes mellitus related comorbidities (DRCs). This study aims to: (i) estimate the incidence of DRCs among cART recipients, (ii) assess the time-to-event (development of DRC) and, (iii) compare survival function between recipients on first-line regimen and those on second-, third-line cART regimen.
The incidence of DRCs was 26.8/1000 person-years, with total time of exposure of 3316 person-years. The average time to event for all the three regimens was 11.72 ± 0.20 years. The first-line cART regimen had a shorter mean ± SE of 10.59 ± 0.26 years to the event compared to 12.69 ± 0.24 years for the second-, third-line cART regimen. Recipients on the first-line had a shorter survival than recipients on second-, third-line cART (Log-rank X
= 8.98, p |
doi_str_mv | 10.1186/s13104-018-3144-9 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b254dd1048f54ddc91a6e98eddb71fce</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A546075038</galeid><doaj_id>oai_doaj_org_article_b254dd1048f54ddc91a6e98eddb71fce</doaj_id><sourcerecordid>A546075038</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5099-b3792cce32a9bc9c45eb3c125b92960b278c0cb699540d7e93618b1e3f4319ce3</originalsourceid><addsrcrecordid>eNptUstu1DAUjRCIlsIHsEGW2MAixY84iVlUKhXQkSp1A91aftxMPUrswXZa-iH8L56ZUjoIeWH7-pxz5XNPVb0m-JiQvv2QCCO4qTHpa0aaphZPqkPS8bbGHOOnj84H1YuUVhi3pO_J8-qACiYIZuKw-rXwxlnwBlAYkHVKQ4aEJhhHl-dURxhVBotMmELUzrrsyrOagl-itSoXn8s1Z_DWlVK-DWhSqxDR-eIKmdF5ZxJyHn0KOd0qrz4ihQit70BFFCHHkNZgsruB0uE6xIxSnu3dy-rZoMYEr-73o-r7l8_fzs7ri8uvi7PTi9pwLEStWSeoMcCoEtoI03DQzBDKtaCixZp2vcFGt0LwBtsOBCsGaAJsaBgRhXdULXa6NqiVXEc3qXgng3JyWwhxKVXMzowgNeWNtcXuftgcjCCqBdGDtbojw1brZKe1nvUE1hRnohr3RPdfvLuWy3AjeSfahvVF4N29QAw_ZkhZTi6ZMgjlIcxJElGmJjijTYG-_Qe6CnP0xSpJO0EYpViwv6ilKh9wfgilr9mIylPetLjjeNv2-D-osixMzgQPgyv1PcL7PULBZPiZl2pOSS4ur_axZIc1ZdIpwvDgB8Fyk2G5y7AsGZabDEtROG8eG_nA-BNa9hsPi-0n</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2791322093</pqid></control><display><type>article</type><title>Incidence of diabetes mellitus-related comorbidities among patients attending two major HIV clinics in Botswana: a 12-year retrospective cohort study</title><source>PMC</source><source>ProQuest - Publicly Available Content Database</source><creator>Rankgoane-Pono, Goabaone ; Tshikuka, Jose Gaby ; Magafu, Mgaywa Gilbert Mjungu Damas ; Masupe, Tiny ; Molefi, Mooketsi ; Hamda, Shimeles Genna ; Setlhare, Vincent ; Tapera, Roy ; Mbongwe, Bontle</creator><creatorcontrib>Rankgoane-Pono, Goabaone ; Tshikuka, Jose Gaby ; Magafu, Mgaywa Gilbert Mjungu Damas ; Masupe, Tiny ; Molefi, Mooketsi ; Hamda, Shimeles Genna ; Setlhare, Vincent ; Tapera, Roy ; Mbongwe, Bontle</creatorcontrib><description>Exposure to combination antiretroviral therapy (cART) is associated with the development of diabetes mellitus related comorbidities (DRCs). This study aims to: (i) estimate the incidence of DRCs among cART recipients, (ii) assess the time-to-event (development of DRC) and, (iii) compare survival function between recipients on first-line regimen and those on second-, third-line cART regimen.
The incidence of DRCs was 26.8/1000 person-years, with total time of exposure of 3316 person-years. The average time to event for all the three regimens was 11.72 ± 0.20 years. The first-line cART regimen had a shorter mean ± SE of 10.59 ± 0.26 years to the event compared to 12.69 ± 0.24 years for the second-, third-line cART regimen. Recipients on the first-line had a shorter survival than recipients on second-, third-line cART (Log-rank X
= 8.98, p < 0.003). Data from this study showed that the risk of developing DRCs per year of exposure was significantly greater for patients on first-line compared to those who were on second-, third-line regimen; which, suggests that monitoring of cART long-term side effects and regular reviewing of cART regimens is important. Meticulous selection of drug combinations is a key to improving recipients' survival.</description><identifier>ISSN: 1756-0500</identifier><identifier>EISSN: 1756-0500</identifier><identifier>DOI: 10.1186/s13104-018-3144-9</identifier><identifier>PMID: 29391039</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Acquired immune deficiency syndrome ; AIDS ; Analysis ; Antiretroviral therapy ; Botswana ; Cohort analysis ; Combination antiretroviral therapy ; Comorbidity ; Complications and side effects ; Data collection ; Development and progression ; Diabetes ; Diabetes mellitus ; Diabetes-related comorbidities ; Distribution ; Drug therapy ; Health aspects ; Highly active antiretroviral therapy ; HIV ; HIV carriers ; Human immunodeficiency virus ; Incidence ; Medical records ; Patients ; PLHIV ; Research Note ; Sample size ; Survival ; Survival analysis ; Type 2 diabetes</subject><ispartof>BMC research notes, 2018-02, Vol.11 (1), p.90-90, Article 90</ispartof><rights>COPYRIGHT 2018 BioMed Central Ltd.</rights><rights>2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5099-b3792cce32a9bc9c45eb3c125b92960b278c0cb699540d7e93618b1e3f4319ce3</citedby><cites>FETCH-LOGICAL-c5099-b3792cce32a9bc9c45eb3c125b92960b278c0cb699540d7e93618b1e3f4319ce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796438/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2791322093?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29391039$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rankgoane-Pono, Goabaone</creatorcontrib><creatorcontrib>Tshikuka, Jose Gaby</creatorcontrib><creatorcontrib>Magafu, Mgaywa Gilbert Mjungu Damas</creatorcontrib><creatorcontrib>Masupe, Tiny</creatorcontrib><creatorcontrib>Molefi, Mooketsi</creatorcontrib><creatorcontrib>Hamda, Shimeles Genna</creatorcontrib><creatorcontrib>Setlhare, Vincent</creatorcontrib><creatorcontrib>Tapera, Roy</creatorcontrib><creatorcontrib>Mbongwe, Bontle</creatorcontrib><title>Incidence of diabetes mellitus-related comorbidities among patients attending two major HIV clinics in Botswana: a 12-year retrospective cohort study</title><title>BMC research notes</title><addtitle>BMC Res Notes</addtitle><description>Exposure to combination antiretroviral therapy (cART) is associated with the development of diabetes mellitus related comorbidities (DRCs). This study aims to: (i) estimate the incidence of DRCs among cART recipients, (ii) assess the time-to-event (development of DRC) and, (iii) compare survival function between recipients on first-line regimen and those on second-, third-line cART regimen.
The incidence of DRCs was 26.8/1000 person-years, with total time of exposure of 3316 person-years. The average time to event for all the three regimens was 11.72 ± 0.20 years. The first-line cART regimen had a shorter mean ± SE of 10.59 ± 0.26 years to the event compared to 12.69 ± 0.24 years for the second-, third-line cART regimen. Recipients on the first-line had a shorter survival than recipients on second-, third-line cART (Log-rank X
= 8.98, p < 0.003). Data from this study showed that the risk of developing DRCs per year of exposure was significantly greater for patients on first-line compared to those who were on second-, third-line regimen; which, suggests that monitoring of cART long-term side effects and regular reviewing of cART regimens is important. Meticulous selection of drug combinations is a key to improving recipients' survival.</description><subject>Acquired immune deficiency syndrome</subject><subject>AIDS</subject><subject>Analysis</subject><subject>Antiretroviral therapy</subject><subject>Botswana</subject><subject>Cohort analysis</subject><subject>Combination antiretroviral therapy</subject><subject>Comorbidity</subject><subject>Complications and side effects</subject><subject>Data collection</subject><subject>Development and progression</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes-related comorbidities</subject><subject>Distribution</subject><subject>Drug therapy</subject><subject>Health aspects</subject><subject>Highly active antiretroviral therapy</subject><subject>HIV</subject><subject>HIV carriers</subject><subject>Human immunodeficiency virus</subject><subject>Incidence</subject><subject>Medical records</subject><subject>Patients</subject><subject>PLHIV</subject><subject>Research Note</subject><subject>Sample size</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Type 2 diabetes</subject><issn>1756-0500</issn><issn>1756-0500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUstu1DAUjRCIlsIHsEGW2MAixY84iVlUKhXQkSp1A91aftxMPUrswXZa-iH8L56ZUjoIeWH7-pxz5XNPVb0m-JiQvv2QCCO4qTHpa0aaphZPqkPS8bbGHOOnj84H1YuUVhi3pO_J8-qACiYIZuKw-rXwxlnwBlAYkHVKQ4aEJhhHl-dURxhVBotMmELUzrrsyrOagl-itSoXn8s1Z_DWlVK-DWhSqxDR-eIKmdF5ZxJyHn0KOd0qrz4ihQit70BFFCHHkNZgsruB0uE6xIxSnu3dy-rZoMYEr-73o-r7l8_fzs7ri8uvi7PTi9pwLEStWSeoMcCoEtoI03DQzBDKtaCixZp2vcFGt0LwBtsOBCsGaAJsaBgRhXdULXa6NqiVXEc3qXgng3JyWwhxKVXMzowgNeWNtcXuftgcjCCqBdGDtbojw1brZKe1nvUE1hRnohr3RPdfvLuWy3AjeSfahvVF4N29QAw_ZkhZTi6ZMgjlIcxJElGmJjijTYG-_Qe6CnP0xSpJO0EYpViwv6ilKh9wfgilr9mIylPetLjjeNv2-D-osixMzgQPgyv1PcL7PULBZPiZl2pOSS4ur_axZIc1ZdIpwvDgB8Fyk2G5y7AsGZabDEtROG8eG_nA-BNa9hsPi-0n</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Rankgoane-Pono, Goabaone</creator><creator>Tshikuka, Jose Gaby</creator><creator>Magafu, Mgaywa Gilbert Mjungu Damas</creator><creator>Masupe, Tiny</creator><creator>Molefi, Mooketsi</creator><creator>Hamda, Shimeles Genna</creator><creator>Setlhare, Vincent</creator><creator>Tapera, Roy</creator><creator>Mbongwe, Bontle</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180201</creationdate><title>Incidence of diabetes mellitus-related comorbidities among patients attending two major HIV clinics in Botswana: a 12-year retrospective cohort study</title><author>Rankgoane-Pono, Goabaone ; Tshikuka, Jose Gaby ; Magafu, Mgaywa Gilbert Mjungu Damas ; Masupe, Tiny ; Molefi, Mooketsi ; Hamda, Shimeles Genna ; Setlhare, Vincent ; Tapera, Roy ; Mbongwe, Bontle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5099-b3792cce32a9bc9c45eb3c125b92960b278c0cb699540d7e93618b1e3f4319ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>AIDS</topic><topic>Analysis</topic><topic>Antiretroviral therapy</topic><topic>Botswana</topic><topic>Cohort analysis</topic><topic>Combination antiretroviral therapy</topic><topic>Comorbidity</topic><topic>Complications and side effects</topic><topic>Data collection</topic><topic>Development and progression</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes-related comorbidities</topic><topic>Distribution</topic><topic>Drug therapy</topic><topic>Health aspects</topic><topic>Highly active antiretroviral therapy</topic><topic>HIV</topic><topic>HIV carriers</topic><topic>Human immunodeficiency virus</topic><topic>Incidence</topic><topic>Medical records</topic><topic>Patients</topic><topic>PLHIV</topic><topic>Research Note</topic><topic>Sample size</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rankgoane-Pono, Goabaone</creatorcontrib><creatorcontrib>Tshikuka, Jose Gaby</creatorcontrib><creatorcontrib>Magafu, Mgaywa Gilbert Mjungu Damas</creatorcontrib><creatorcontrib>Masupe, Tiny</creatorcontrib><creatorcontrib>Molefi, Mooketsi</creatorcontrib><creatorcontrib>Hamda, Shimeles Genna</creatorcontrib><creatorcontrib>Setlhare, Vincent</creatorcontrib><creatorcontrib>Tapera, Roy</creatorcontrib><creatorcontrib>Mbongwe, Bontle</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Opposing Viewpoints Resource Center</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC research notes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rankgoane-Pono, Goabaone</au><au>Tshikuka, Jose Gaby</au><au>Magafu, Mgaywa Gilbert Mjungu Damas</au><au>Masupe, Tiny</au><au>Molefi, Mooketsi</au><au>Hamda, Shimeles Genna</au><au>Setlhare, Vincent</au><au>Tapera, Roy</au><au>Mbongwe, Bontle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence of diabetes mellitus-related comorbidities among patients attending two major HIV clinics in Botswana: a 12-year retrospective cohort study</atitle><jtitle>BMC research notes</jtitle><addtitle>BMC Res Notes</addtitle><date>2018-02-01</date><risdate>2018</risdate><volume>11</volume><issue>1</issue><spage>90</spage><epage>90</epage><pages>90-90</pages><artnum>90</artnum><issn>1756-0500</issn><eissn>1756-0500</eissn><abstract>Exposure to combination antiretroviral therapy (cART) is associated with the development of diabetes mellitus related comorbidities (DRCs). This study aims to: (i) estimate the incidence of DRCs among cART recipients, (ii) assess the time-to-event (development of DRC) and, (iii) compare survival function between recipients on first-line regimen and those on second-, third-line cART regimen.
The incidence of DRCs was 26.8/1000 person-years, with total time of exposure of 3316 person-years. The average time to event for all the three regimens was 11.72 ± 0.20 years. The first-line cART regimen had a shorter mean ± SE of 10.59 ± 0.26 years to the event compared to 12.69 ± 0.24 years for the second-, third-line cART regimen. Recipients on the first-line had a shorter survival than recipients on second-, third-line cART (Log-rank X
= 8.98, p < 0.003). Data from this study showed that the risk of developing DRCs per year of exposure was significantly greater for patients on first-line compared to those who were on second-, third-line regimen; which, suggests that monitoring of cART long-term side effects and regular reviewing of cART regimens is important. Meticulous selection of drug combinations is a key to improving recipients' survival.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>29391039</pmid><doi>10.1186/s13104-018-3144-9</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1756-0500 |
ispartof | BMC research notes, 2018-02, Vol.11 (1), p.90-90, Article 90 |
issn | 1756-0500 1756-0500 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_b254dd1048f54ddc91a6e98eddb71fce |
source | PMC; ProQuest - Publicly Available Content Database |
subjects | Acquired immune deficiency syndrome AIDS Analysis Antiretroviral therapy Botswana Cohort analysis Combination antiretroviral therapy Comorbidity Complications and side effects Data collection Development and progression Diabetes Diabetes mellitus Diabetes-related comorbidities Distribution Drug therapy Health aspects Highly active antiretroviral therapy HIV HIV carriers Human immunodeficiency virus Incidence Medical records Patients PLHIV Research Note Sample size Survival Survival analysis Type 2 diabetes |
title | Incidence of diabetes mellitus-related comorbidities among patients attending two major HIV clinics in Botswana: a 12-year retrospective cohort study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T06%3A00%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20of%20diabetes%20mellitus-related%20comorbidities%20among%20patients%20attending%20two%20major%20HIV%20clinics%20in%20Botswana:%20a%2012-year%20retrospective%20cohort%20study&rft.jtitle=BMC%20research%20notes&rft.au=Rankgoane-Pono,%20Goabaone&rft.date=2018-02-01&rft.volume=11&rft.issue=1&rft.spage=90&rft.epage=90&rft.pages=90-90&rft.artnum=90&rft.issn=1756-0500&rft.eissn=1756-0500&rft_id=info:doi/10.1186/s13104-018-3144-9&rft_dat=%3Cgale_doaj_%3EA546075038%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5099-b3792cce32a9bc9c45eb3c125b92960b278c0cb699540d7e93618b1e3f4319ce3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2791322093&rft_id=info:pmid/29391039&rft_galeid=A546075038&rfr_iscdi=true |